Hanmi Science Asset Resilience Ratio
Hanmi Science asset resilience ratio. Hanmi Science (008930) has an Asset Resilience Ratio of 0.04% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Hanmi Science to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hanmi Science (2000–2025)
Asset resilience ratio of Hanmi Science from 2000 to 2025. This chart shows how Hanmi Science's Asset Resilience Ratio has changed over time. Read total liabilities of Hanmi Science for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hanmi Science's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 008930 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩636.08 Million | 0.04% |
| Total Liquid Assets | ₩636.08 Million | 0.04% |
Asset Resilience Insights
- Limited Liquidity: Hanmi Science maintains only 0.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hanmi Science Industry Peers by Asset Resilience Ratio
Compare Hanmi Science's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Paragon Care Ltd
AU:PGC |
Medical Distribution | 0.00% |
|
TELES Informationstechnologien AG
XETRA:TLIK |
Medical Distribution | 0.37% |
|
Sigma Healthcare Ltd
AU:SIG |
Medical Distribution | 0.03% |
|
Ebos Group Ltd
AU:EBO |
Medical Distribution | 0.00% |
|
Mayne Pharma Group Ltd
AU:MYX |
Medical Distribution | 4.00% |
|
Profarma Distribuidora de Produtos Farmacêuticos S.A
SA:PFRM3 |
Medical Distribution | 4.48% |
|
Shanghai Pharmaceuticals Holding Co Ltd
SHG:601607 |
Medical Distribution | 3.91% |
|
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SHG:600332 |
Medical Distribution | 0.00% |
Hanmi Science Asset Resilience Ratio by Year (2000–2025)
Hanmi Science asset resilience ratio by year from 2000 to 2025. The table below shows the annual Asset Resilience Ratio data for Hanmi Science.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.05% | ₩783.60 Million ≈ $531.04K |
₩1.49 Trillion ≈ $1.01 Billion |
-0.25pp |
| 2024-12-31 | 0.30% | ₩4.02 Billion ≈ $2.72 Million |
₩1.35 Trillion ≈ $914.25 Million |
-0.27pp |
| 2023-12-31 | 0.57% | ₩6.93 Billion ≈ $4.70 Million |
₩1.23 Trillion ≈ $830.96 Million |
+0.56pp |
| 2022-12-31 | 0.01% | ₩92.75 Million ≈ $62.86K |
₩1.11 Trillion ≈ $752.02 Million |
+0.00pp |
| 2021-12-31 | 0.00% | ₩38.55 Million ≈ $26.12K |
₩949.89 Billion ≈ $643.73 Million |
-0.02pp |
| 2020-12-31 | 0.02% | ₩177.73 Million ≈ $120.45K |
₩923.22 Billion ≈ $625.65 Million |
-0.02pp |
| 2019-12-31 | 0.04% | ₩363.98 Million ≈ $246.66K |
₩910.83 Billion ≈ $617.26 Million |
-0.54pp |
| 2017-12-31 | 0.58% | ₩5.49 Billion ≈ $3.72 Million |
₩938.78 Billion ≈ $636.20 Million |
+0.21pp |
| 2010-12-31 | 0.38% | ₩3.89 Billion ≈ $2.63 Million |
₩1.03 Trillion ≈ $697.86 Million |
+0.34pp |
| 2009-12-31 | 0.03% | ₩312.36 Million ≈ $211.68K |
₩895.44 Billion ≈ $606.83 Million |
-0.10pp |
| 2008-12-31 | 0.14% | ₩1.15 Billion ≈ $781.98K |
₩838.43 Billion ≈ $568.19 Million |
-0.13pp |
| 2007-12-31 | 0.26% | ₩1.82 Billion ≈ $1.23 Million |
₩690.20 Billion ≈ $467.74 Million |
-0.15pp |
| 2006-12-31 | 0.42% | ₩2.18 Billion ≈ $1.48 Million |
₩525.55 Billion ≈ $356.16 Million |
+0.30pp |
| 2005-12-31 | 0.12% | ₩478.43 Million ≈ $324.22K |
₩408.94 Billion ≈ $277.13 Million |
-1.36pp |
| 2004-12-31 | 1.48% | ₩5.40 Billion ≈ $3.66 Million |
₩364.87 Billion ≈ $247.27 Million |
-0.55pp |
| 2003-12-31 | 2.03% | ₩6.66 Billion ≈ $4.52 Million |
₩327.82 Billion ≈ $222.16 Million |
-0.61pp |
| 2002-12-31 | 2.64% | ₩8.07 Billion ≈ $5.47 Million |
₩305.50 Billion ≈ $207.04 Million |
-0.82pp |
| 2001-12-31 | 3.46% | ₩10.24 Billion ≈ $6.94 Million |
₩295.82 Billion ≈ $200.48 Million |
+0.90pp |
| 2000-12-31 | 2.56% | ₩6.32 Billion ≈ $4.28 Million |
₩247.17 Billion ≈ $167.50 Million |
-- |
About Hanmi Science
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition… Read more